Gan & Lee Pharmaceuticals. Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals.

603087

Classificação em ações #3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Preço da ação
$10.03
Valor de mercado
$5.99B
Variação (1 dia)
-3.71%
Variação (1 ano)
2.30%
País
CN
Negociar Gan & Lee Pharmaceuticals. (603087)

Categoria

Healthcare
EPS de Gan & Lee Pharmaceuticals. (603087)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Gan & Lee Pharmaceuticals., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Gan & Lee Pharmaceuticals. de 2013 até 2026
EPS no final de cada ano
Ano EPS Alterar
2025 $0.28 93.61%
2024 $0.14 68.04%
2023 $0.08 -174.98%
2022 $-0.11 -127.75%
2021 $0.41 21.57%
2020 $0.34 12.22%
2019 $0.30 11.04%
2018 $0.27 -18.21%
2017 $0.33 50.25%
2016 $0.22 59.66%
2015 $0.14 39.19%
2014 $0.10 35.86%
2013 $0.07 0.00%
EPS de empresas semelhantes ou concorrentes